PT-141
Bremelanotide
Arousal that starts in the brain, not the bloodstream — a melanocortin agonist taken before sex. It’s one of the few peptides here with an FDA-approved form.
What it is
Raises sexual desire and arousal centrally — and notably in women as well as men, which is the angle the community returns to most. It’s taken occasionally, ahead of activity, not on a daily schedule.
It works a step upstream of the erectile-dysfunction drugs. Those act on blood flow; PT-141 acts on the brain’s arousal pathway itself — which is why it’s reported to lift desire rather than just mechanics, and why it works for women too. The same melanocortin pathway is responsible for its signature quirk: temporary skin darkening, the same mechanism as the tanning peptide Melanotan.
Mechanism
Activates melanocortin receptors (chiefly MC4R) in the central nervous system — upstream of the vascular pathway that erectile-dysfunction drugs target. That central action is why the effect is desire, not just blood flow, and why it isn’t sex-specific. Activation of MC1R in the skin is what drives the pigment/darkening side effect.
Step 1 · the usual approach
Most drugs work on the plumbing.
The familiar ED pills act downstream — they relax blood vessels so more blood can flow in. Useful, but purely mechanical: they do nothing for desire itself, only the hardware.
Step 2 · a different target
PT-141 aims higher up.
Instead of the blood vessels, PT-141 goes after the brain. It’s reaching for the part of the system that sets desire in motion in the first place — upstream of everything the plumbing drugs touch.
Step 3 · into the brain
It reaches the central nervous system.
Pinned subcutaneously (or taken intranasally), PT-141 crosses into the CNS and heads for a specific family of receptors in the hypothalamus — the brain’s control room for drives like hunger and arousal.
Step 4 · the switch
It flips the melanocortin MC4R switch.
It activates melanocortin receptors — chiefly MC4R. This is the desire switch itself, sitting upstream of the vascular pathway the ED drugs target. Flip it, and the signal originates in the brain, not the bloodstream.
Step 5 · the signal travels
Arousal signaling cascades down.
From the hypothalamus the signal propagates down through the nervous system — desire registering centrally first, then driving the downstream physical response. Cause, not just effect.
Step 6 · the side effect
A cousin receptor causes flushing.
MC4R has a relative in your skin — MC1R, the pigment receptor. PT-141 nudges it too, which is why flushing, skin darkening, and some nausea are the common, well-documented side effects.
Step 7 · the evidence
And this one has real backing.
Unlike most peptides here, PT-141 is clinically validated: as bremelanotide it’s FDA-approved for low sexual desire in women. The mechanism isn’t theoretical — it’s on a label.
The result
Desire at the source, not the symptom.
By acting on the brain’s desire pathway rather than the blood vessels, PT-141 addresses arousal at its origin — a fundamentally different lever than the plumbing-focused drugs it sits upstream of.
The clinical outlier here — approved as bremelanotide. Flushing, skin darkening, and nausea are common, documented side effects.
Standard dose
| Standard dose | 1–2 mg per use; ~1.75 mg most-cited (proposed — pending dosing review)community |
|---|---|
| Start low | Begin ~0.5–1 mg and titrate — side effects scale with dosecommunity |
| Timing | ~45 min to 2 hours before activity; onset is slow and variablecommunity |
| Route / frequency | SubQ; as-needed, not dailycommunity |
Reconstitution calculator
U-100 · 100u = 1 mL= 200 units
Set the vial size and water to match your product — amounts vary by supplier. This is unit-conversion math, not medical advice or a dosing recommendation.
Pushing higher— going beyond the standard dosecommunity
Side effects & cautions
Nausea is the defining side effect and the main reason people titrate down — it’s dose-dependent and very commonly reported. Temporary skin darkening (the melanocortin/MC1R pathway, same as Melanotan) is nearly as common, along with facial flushing and headache. Because there’s an FDA-approved version, the side-effect profile here is better characterized than most peptides on this site — and nausea is right at the top of the label too.
Stacking
Largely a standalone, as-needed peptide rather than a stack component — it’s taken before activity, not run on a schedule, so it doesn’t pair into daily protocols the way the GH or repair peptides do.
Evidence & sources
The most evidence-backed peptide here: FDA-approved for low desire in women, on replicated Phase III RCTs. Note the effect size is modest, and the earlier erectile-dysfunction program was halted over blood-pressure concerns — it was never approved for men.
- Kingsberg SA et al. (2019)Human RCTRECONNECT — bremelanotide for HSDD (Phase III)Obstet Gynecol — pivotal RCTPMID 31599840 ↗
- Simon JA et al. (2019)Human RCTRECONNECT open-label extensionObstet Gynecol — long-term humanPMID 31599847 ↗
- Pfaus JG et al. (2004)Animal / in-vitroMelanocortin activation and sexual behaviorPNAS — mechanismPMID 15226502 ↗
- U.S. FDA (2019)RegulatoryBremelanotide approval for HSDDFDA NDA 210557NCT02333071 ↗